Pharmaceutical Company Alcobra Raises $25M On IPO

Israeli company Alcobra Pharmaceuticals, which is developing medication to treat Attention Deficit Hyperactive Disorder (ADHD), has raised $25 million in a Nasdaq IPO. The company is valued at $113 million and will be traded under the ticker ADHD.

The IPO exceeds the company’s estimate, which was to raise $15-20 million at a company value of $100 million.